| General Information | |
|---|---|
| ZINC ID | ZINC000013742570 |
| Molecular Weight (Da) | 413 |
| SMILES | Cc1c(C(=O)c2cccc3ccccc23)c2ccccc2n1CCN1CCOC[C@@H]1C |
| Molecular Formula | C27N2O2 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 123.359 |
| HBA | 2 |
| HBD | 0 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 31 |
| LogP | 4.901 |
| Activity (Ki) in nM | 380.189 |
| Polar Surface Area (PSA) | 34.47 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | + |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.9953165 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 19 |
| Fraction csp3 | 0.3 |
| Ilogp | 3.58 |
| Xlogp3 | 5.02 |
| Wlogp | 4.67 |
| Mlogp | 3.07 |
| Silicos-it log p | 5.24 |
| Consensus log p | 4.32 |
| Esol log s | -5.68 |
| Esol solubility (mg/ml) | 0.000854 |
| Esol solubility (mol/l) | 0.00000207 |
| Esol class | Moderately |
| Ali log s | -5.48 |
| Ali solubility (mg/ml) | 0.00135 |
| Ali solubility (mol/l) | 0.00000328 |
| Ali class | Moderately |
| Silicos-it logsw | -8.05 |
| Silicos-it solubility (mg/ml) | 0.00000369 |
| Silicos-it solubility (mol/l) | 8.93E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.25 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.65 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.183 |
| Logd | 4.046 |
| Logp | 4.969 |
| F (20%) | 0.039 |
| F (30%) | 0.611 |
| Mdck | - |
| Ppb | 97.64% |
| Vdss | 2.663 |
| Fu | 0.97% |
| Cyp1a2-inh | 0.704 |
| Cyp1a2-sub | 0.924 |
| Cyp2c19-inh | 0.685 |
| Cyp2c19-sub | 0.28 |
| Cl | 7.11 |
| T12 | 0.009 |
| H-ht | 0.886 |
| Dili | 0.853 |
| Roa | 0.342 |
| Fdamdd | 0.565 |
| Skinsen | 0.095 |
| Ec | 0.003 |
| Ei | 0.063 |
| Respiratory | 0.429 |
| Bcf | 2.218 |
| Igc50 | 4.922 |
| Lc50 | 5.783 |
| Lc50dm | 6.533 |
| Nr-ar | 0.052 |
| Nr-ar-lbd | 0.007 |
| Nr-ahr | 0.767 |
| Nr-aromatase | 0.541 |
| Nr-er | 0.284 |
| Nr-er-lbd | 0.041 |
| Nr-ppar-gamma | 0.003 |
| Sr-are | 0.552 |
| Sr-atad5 | 0.008 |
| Sr-hse | 0.006 |
| Sr-mmp | 0.36 |
| Sr-p53 | 0.246 |
| Vol | 445.975 |
| Dense | 0.924 |
| Flex | 0.179 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 4 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 3 |
| Qed | 0.43 |
| Synth | 2.829 |
| Fsp3 | 0.296 |
| Mce-18 | 83.943 |
| Natural product-likeness | -0.898 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |